The current COVID-19 pandemic has highlighted the risk faced by older adults, who are more susceptible to complications, including acute respiratory distress syndrome, usually due to pneumonia, which increases the risk of developing sepsis. Thus, increasing the need for early diagnosis of sepsis among patients with covid-19 infections.



The COVID-19 pandemic had a moderately positive effect on the sales of diagnostics products for sepsis. The global spread of covid-19 and the emerging cases of sepsis among covid-19 patients are likely to increase the demand for rapid diagnosis, accelerating the utilization of instruments, reagents, & assay kits for detection of sepsis.



Sepsis is a very difficult condition to diagnose and the risk of mortality increases by 7.6% with a delay of even 1 minute in antibiotic administration in septic shock patients with hypertension. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis.



Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The shortage of skilled professionals is a major concern worldwide; only 50% of patients with severe sepsis transported by the EMS system have a paramedic.



09976cbf42661c1b67146fb63ba1f6b7.jpg

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155



[236 Pages Report] The global sepsis diagnostics size is expected to reach USD 771 million by 2026 from USD 503 million in 2021, at a CAGR of 8.9%. The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for sepsis diagnostic research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.



Based on end-user, the market is segmented into hospitals and specialty clinics, pathology & reference laboratories, and research laboratories & academic institutes. The hospitals and specialty clinics accounted for the largest share of the sepsis diagnostics industry.



The larger share of this segment can be attributed to the high prevalence of sepsis coupled with a large number of fatalities caused by the illness, increasing number of patients hospitalized with sepsis, and in-house hospital laboratories perform a large number of blood culture tests to identify the blood stream infections (BSIs caused by bacteria, fungi/yeast, or viruses).



The prominent players operating in the global sepsis diagnostics market include bioMérieux (France), Becton, Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), Luminex (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), Immunexpress (Australia), Axis-Shield Diagnostics (UK), Quidel Corporation (US), Siemens Healthineers (Germany).